Conclusion: Findings for other SUDs were mixed, though psilocybin showed potential in reducing opioid dependence and nicotine use. Preliminary evidence supports psilocybin's efficacy and safety for AUD and TUD, particularly with psychotherapy, but larger clinical trials are needed to confirm these findings.
PubMed 40245969 ↗Psilocybin Microdose
The short answer. There isn't much data on Psilocybin Microdose yet — 38 mentions, 14 with a clear outcome — so treat these numbers as anecdotal. It is most often used for mood: 100% of 11 reports say that improved. There is a moderate body of research — 13 meta-analyses and 0 trials.
From 38 mentions in total — the rest didn't say how it went and aren't counted.
What Psilocybin Microdose does, according to users
Of the people who reported each effect, the share who said it got better.
5 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
At least one meta-analysis, or 5+ randomized controlled trials. The grade measures how much human research exists — read the conclusions below for what it found. 13 meta-analyses on PubMed ↗ · 0 randomized trials ↗
Conclusion: Prim Care Companion CNS Disord 2024;26(1):23r03581. Author affiliations are listed at the end of this article.
PubMed 38228068 ↗Conclusion: Our review concludes that it is premature to draw any conclusions about the efficacy or safety of microdosing since the research quality cannot be considered confirmatory. We propose some potential causes for the current state of the literature and some suggestions for how these causes may be ameliorated.
PubMed 38374976 ↗Conclusion: However, better distinguishing between on-drug and off-drug effects is essential for clarifying whether microdosing exerts only transient pharmacological influences or promotes lasting cognitive change. Given the methodological heterogeneity across studies, future research using standardized protocols and mechanistic approaches is needed to fully characterize the cognitive and neural effects of microdosing classical psychedelics.
PubMed 41314362 ↗7 human trials on ClinicalTrials.gov test Psilocybin Microdose — 1 completed, 3 recruiting now. See all on ClinicalTrials.gov ↗
- Safety for Home Administration of Microdose Psilocybin Use · Psychedelic Experiences · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Psilocybin Microdose is a Schedule I controlled substance in the US (listed as Psilocybin). DEA controlled-substance list ↗
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I do a microdose with some reishi and lions mane for nerve pains and it works wonderfully. Only problem is that tolerance comes pretty quickly so I limit how often I take it.”
“First time was great, but I got nausea every other time.”
“I found it has made me a lot more creative and better at thinking outside the box.”
“I went down the adderall and vyvanse rabbit hole... Still had some profoundly negative impacts on my life... micro dosing psilocybin helps alot ...like it helped me ALOT!”
Psilocybin Microdose compared
Other options for mood
Sources
- User reports: 38 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- US DEA ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate